PaxMedica Inc PXMD:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 09/29/22 EDT
2.42quote price arrow down-0.03 (-1.22%)
Volume
2,098
Close
2.45UNCH (UNCH)
Volume
261,019
52 week range
2.04 - 10.48
Loading...
  • Open2.47
  • Day High2.53
  • Day Low2.25
  • Prev Close2.52
  • 52 Week High10.48
  • 52 Week High Date08/26/22
  • 52 Week Low2.04
  • 52 Week Low Date09/26/22

Key Stats

  • Market Cap24.55M
  • Shares Out10.02M
  • 10 Day Average Volume1.47M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open2.47
  • Day High2.53
  • Day Low2.25
  • Prev Close2.52
  • 52 Week High10.48
  • 52 Week High Date08/26/22
  • 52 Week Low2.04
  • 52 Week Low Date09/26/22
  • Market Cap24.55M
  • Shares Out10.02M
  • 10 Day Average Volume1.47M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-0.08
  • P/E (TTM)-30.81
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-759,450.00
  • ROE (TTM)-
  • Revenue (TTM)0.00
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On PaxMedica Inc

 

Profile

MORE
PaxMedica, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Its product candidates include PAX-101 and PAX-102. Its lead program, PAX-101, is an intravenous...
Michael Derby
Chairman of the Board, Founder
Howard Weisman
Chief Executive Officer
Zachary Rome
Chief Operating Officer, Director
Joseph Lucchese
Chief Financial Officer
Address
303 South Broadway, Suite 125
Tarrytown, NY
10591
United States